Abstract-Central effect of thyrotropin releasing hormone (TRH) on gastric acid output and mucosal blood flow (MBF) was examined in urethane anesthetized rats. TRH, microinjected into the dorsal vagal complex [the dorsal motor nucleus of the vagus (NDV), the nucleus tractus solitarius and area postrema] induced dose-dependent (0.5-50 pmole) increases in gastric acid output and MBF. In contrast, 5 pmole TRH microinjected into various hypothalamic regions had no effect on these gastric parameters.
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Administration of TRH intraventricularly (i.c.v.) also increased these gastric parameters; however, about a 10 times higher dose of TRH was required to obtain the same order of excitatory effects seen with micro injection to the dorsal vagal complex.
Application of anti-TRH serum to the dorsal vagal complex inhibited the increases in gastric acid output and MBF induced by TRH (i.c.v.). The effect of TRH applied to the dorsal vagal complex and i.c.v. were not modified by a concomitant administration of atropine. These results suggests that NDV is probably the site of action of TRH in inducing gastric hyper functions.
The mode of action of TRH seems to be independent of cholinergic muscarinic mechanisms present in the NDV. 
Materials and Methods
Male Wistar rats weighing 220-250 g were maintained in a room at 22-24°C under a constant day-night rhythm for 7-10 days and given food (laboratory chow, CE-2, Japan Clea Co.) and tap water, ad libitum. Prior to each experiment, all food but not water was withheld for 16 hr. With the rats under urethane anesthesia (1.1 g/kg, i.p.), the femoral vein and femoral artery were cannulated. The abdomen was opened by a mid-line incision and a round-tip cannula (5 cm long, 0.5 cm outer diameter) connected to a polyethylene tube was inserted into the stomach via an incision into the duodenum (1 cm distal from the pyloric sphincter). The tip of the cannula lay just above the pyloric sphincter and was held in place by two ligatures around the duodenum, one at the point of incision and the other close to the pylorus, as described by Main and Whittle (16). To remove the solid contents, the stomach was flushed with saline, taking care to avoid distention.
After repeated washings, two ml of solution prewarmed to 38'C was placed in the stomach at the beginning of each 15 min collection period. The composition of this solution was a 1.5 (v/v) mixture of glycine and mannitol adjusted to 300 mosM and pH 3. . Thirty min after the priming dose of amino pyrine (30 mg/kg, i.p.), 6.6 mg/kg/hr infusion through the femoral vein was started and was continued throughout the experiment to maintain a constant blood level of amino pyri ne.
The animal was placed in a stereotaxic instrument. Forty-five min were allowed for stabilization of acid and aminopyrine con tents in the gastric juice after the onset of aminopyrine infusion. To ensure that the rats remained in good condition, the total volume of blood samples was kept to a minimum. Samples of arterial blood (0.5 ml) were collected via a cannula inserted into the femoral artery, once 60 min after the onset of aminopyrine infusion and again immediately after the end of the experiment. The plasma level of aminopyrine at each 15 min interval during the experimental period was estimated by interpolation between two measured points and was paired with each amino pyrine determination in the gastric juice. The contents of aminopyrine in the plasma and gastric juice sample were assayed according to Brodie and Axelrod (20). The gastric MBF was calculated from these measurements (21).
Drugs were dissolved in saline and solution containing the test substances was applied to the lateral cerebral ventricle (AP: 7.5, L: 1.1, H: 3.5 mm from the cortical surface) in a volume of 10 /el through a stainless steel micropipette (0.35 mm outer diameter). A glass micropipette (70 ,um outer diameter) was used for the microinjections (in a volume of 0.5 ,ul) of test substances into various hypothalamic regions and an area adjacent to the dorsal motor nucleus of the vagus (NDV) (AP: -6.0, L: 0.5, H: 0.6), within the dorsal vagal complex.
Microinjection of anti-TRH serum into the dorsal vagal complex was performed bilaterally (0.5 /l x2). Anti-TRH serum was obtained as described (22) . The antibody which we used did not cross-react with TRH analogues, amino acids, human pituitary hormones or synthetic LH-RH (23).
After the experiment, the brain was removed, fixed in 10% formalin, and the frozen sections cut at 30 ,um were stained with cresyl violet for microscopic study of microinjection sites. Results were expressed as the mean±S.E. Statistical significance was compared with the corresponding values of control rats using Student's t-test for unpaired comparisons.
Results
The mean basal gastric acid output and MBF obtained from rats under urethane anesthesia were 3.41 ±0.34 ,eEq/1 5 min (n=56) and 1.81±0.13 ml/15 min (n=56), respectively. Intraventricular administration of TRH (0.5-500 pmole) induced dose dependent increases in both gastric acid output and MBF, as previously noted (13, 15) (Fig. 1) . Microinjection of TRH (0.5-50 pmole) into the dorsal vagal complex induced a dose-dependent increase in these gastric parameters (Fig. 2) . With this microinjection of TRH into the dorsal vagal complex, doses as little as one tenth of those given by the i.c.v. route were adequate to obtain the same order of responses (Fig. 3) significantly affect the gastric acid output (data not shown). Pretreatment of anti-TRH serum microinjected into the bilateral dorsal vagal complex significantly inhibited the effects of TRH (50 pmol, i.c.v.) on gastric functions (Fig. 4) .
As related to the induction of gastric hyperfunction by TRH, in another series of experiments, a possible interaction of TRH with the cholinergic muscarinic mechanism was examined at the level of the dorsal vagal complex.
Microinjection of the vehicle (saline) into the dorsal vagal complex slightly increased the gastric acid output, as reported by Kadekaro et al. (24) and in our previous study (25), while microinjection of 3 nmole atropine alone into this region did not induce such an increase. Therefore, the results by administration of TRH were expressed as the net increase in gastric acid output from the respective basal levels, with and without atropine. The increasing effect of 5 pmole TRH microinjected into the dorsal vagal complex was not modified by a concomitant administration of 3 nmole atropine (Fig. 5) The effects of TRH applied to the dorsal vagal complex or i.c.v. were not modified by a concomitant administration of atropine.
The dose of atropine used in the present study was 3 nmol, and this dose micro injected into the dorsal vagal complex completely blocked the increase in gastric acid secretion induced by electrical stimu lation of the lateral hypothalamic area (25). Therefore, TRH probably acts in the NDV, independent of cholinergic muscarinic mechanisms and stimulates gastric acid secretion. Microinjection of test substances in the present experiments was given into an area as adjacently as possible to the NDV within the dorsal vagal complex. However, the possibility that the site of action was the nucleus tractus solitarius but not the NDV cannot be ruled out, since the NDV and the nucleus tractus solitarius are in close proximity, and there is a functional circuit between these two nuclei.
